Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Biofrontera ( (BFRI) ) is now available.
On May 21, 2025, Biofrontera Inc. received a notice from Nasdaq indicating non-compliance with the equity listing requirement, as their stockholders’ equity was reported at $469,000, below the required $2,500,000. The company has 45 days to submit a compliance plan to Nasdaq, and if accepted, they may have up to 180 days to meet the requirements, with the possibility of appealing if the plan is rejected.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall stock score reflects the company’s revenue growth and strategic milestones, but it is heavily weighed down by ongoing unprofitability, high leverage, and weak technical indicators. The Nasdaq non-compliance notice adds further risk to the stock’s stability.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of dermatological products.
Average Trading Volume: 113,971
Technical Sentiment Signal: Sell
Current Market Cap: $6.31M
For detailed information about BFRI stock, go to TipRanks’ Stock Analysis page.